300 related articles for article (PubMed ID: 21677329)
41. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
Ratziu V; Rinella ME; Neuschwander-Tetri BA; Lawitz E; Denham D; Kayali Z; Sheikh A; Kowdley KV; Desta T; Elkhashab M; DeGrauw J; Goodwin B; Ahmad A; Adda N
J Hepatol; 2022 Mar; 76(3):506-517. PubMed ID: 34740705
[TBL] [Abstract][Full Text] [Related]
42. Metadoxine Versus Placebo for the Treatment of Non-alcoholic Steatohepatitis: A Randomized Controlled Trial.
Shenoy KT; Balakumaran LK; Mathew P; Prasad M; Prabhakar B; Sood A; Singh SP; Rao NP; Zargar SA; Bignamini AA
J Clin Exp Hepatol; 2014 Jun; 4(2):94-100. PubMed ID: 25755546
[TBL] [Abstract][Full Text] [Related]
43. Pentoxifylline (PTX)--an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial.
Finamor FE; Martins JR; Nakanami D; Paiva ER; Manso PG; Furlanetto RP
Eur J Ophthalmol; 2004; 14(4):277-83. PubMed ID: 15309971
[TBL] [Abstract][Full Text] [Related]
44. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
[TBL] [Abstract][Full Text] [Related]
45. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
[TBL] [Abstract][Full Text] [Related]
46. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
Sorbi D; Boynton J; Lindor KD
Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
[TBL] [Abstract][Full Text] [Related]
47. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.
Dixon JB; Bhathal PS; O'Brien PE
Obes Surg; 2006 Oct; 16(10):1278-86. PubMed ID: 17059735
[TBL] [Abstract][Full Text] [Related]
48. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
49. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
[TBL] [Abstract][Full Text] [Related]
50. Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials.
Loomba R; Wesley R; Pucino F; Liang TJ; Kleiner DE; Lavine JE
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1243-8. PubMed ID: 18829391
[TBL] [Abstract][Full Text] [Related]
51. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies.
Zeng T; Zhang CL; Zhao XL; Xie KQ
Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):646-53. PubMed ID: 24743504
[TBL] [Abstract][Full Text] [Related]
52. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
53. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
[TBL] [Abstract][Full Text] [Related]
54. Beneficial effects of pentoxifylline pretreatment in non-heart-beating donors in rats.
Astarcioğlu H; Karademir S; Unek T; Ozer E; Menekay S; Coker A; Astarcioğlu I
Transplantation; 2000 Jan; 69(1):93-8. PubMed ID: 10653386
[TBL] [Abstract][Full Text] [Related]
55. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial.
Bril F; Biernacki DM; Kalavalapalli S; Lomonaco R; Subbarayan SK; Lai J; Tio F; Suman A; Orsak BK; Hecht J; Cusi K
Diabetes Care; 2019 Aug; 42(8):1481-1488. PubMed ID: 31332029
[TBL] [Abstract][Full Text] [Related]
56. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V; Bedossa P; Francque SM; Larrey D; Aithal GP; Serfaty L; Voiculescu M; Preotescu L; Nevens F; De Lédinghen V; Kirchner GI; Trunecka P; Ryder SD; Day CP; Takeda J; Traudtner K
Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1724-30.e5. PubMed ID: 24530600
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis.
Kayadibi H; Gültepe M; Yasar B; Ince AT; Ozcan O; Ipcioglu OM; Kurdas OO; Bolat B; Benek YZ; Guveli H; Atalay S; Ozkara S; Keskin O
Dig Dis Sci; 2009 Aug; 54(8):1764-71. PubMed ID: 18989777
[TBL] [Abstract][Full Text] [Related]
58. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.
Escolar DM; Zimmerman A; Bertorini T; Clemens PR; Connolly AM; Mesa L; Gorni K; Kornberg A; Kolski H; Kuntz N; Nevo Y; Tesi-Rocha C; Nagaraju K; Rayavarapu S; Hache LP; Mayhew JE; Florence J; Hu F; Arrieta A; Henricson E; Leshner RT; Mah JK
Neurology; 2012 Mar; 78(12):904-13. PubMed ID: 22402864
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
Zöhrer E; Alisi A; Jahnel J; Mosca A; Della Corte C; Crudele A; Fauler G; Nobili V
Appl Physiol Nutr Metab; 2017 Sep; 42(9):948-954. PubMed ID: 28511023
[TBL] [Abstract][Full Text] [Related]
60. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial.
Abdelmalek MF; Sanderson SO; Angulo P; Soldevila-Pico C; Liu C; Peter J; Keach J; Cave M; Chen T; McClain CJ; Lindor KD
Hepatology; 2009 Dec; 50(6):1818-26. PubMed ID: 19824078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
